

## Gastroesophageal Reflux Disease: PBL

Jason Domagalski, MD, FAAFP

FMX

## ACTIVITY DISCLAIMER

The material presented here is being made available by the American Academy of Family Physicians for educational purposes only. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.

The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Every effort has been made to ensure the accuracy of the data presented here. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.

FMX

## DISCLOSURE

It is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest (COI), and if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity.

All individuals in a position to control content for this activity have indicated they have no relevant financial relationships to disclose.

The content of my material/presentation in this CME activity will include discussion of unapproved or investigational uses of products or devices as indicated. MUSE system is under clinical trials.

FMX

## Jason Domagalski, MD, FAAFP

Program Director, Medical College of Wisconsin Affiliated Hospitals Community Memorial Hospital Family Medicine Residency, Menomonee Falls, WI.

Dr. Domagalski practices family medicine in Menomonee Falls, WI. He provides outpatient and inpatient services. Colon cancer screening, GERD, and inflammatory bowel disease are his specialty topics. Dr. Domagalski believes that access to endoscopy through primary care is an important trend.

FMX

## Learning Objectives

1. Practice applying new knowledge and competencies gained from gastroesophageal reflux disease sessions, and receive feedback from expert faculty.
2. Interact collaboratively with peers to solve complex and challenging case-study scenarios.
3. Develop problem-solving skills that promote effective reasoning to manage gastroesophageal reflux disease within the context of professional practice.

FMX

## Audience Engagement System

The image shows three sequential screenshots of a mobile application interface for an audience engagement system. Step 1 shows a home screen with a navigation bar at the top and a grid of icons for various features. Step 2 shows a list of CME activities with details such as title, date, and duration. Step 3 shows a detailed view of a specific CME activity, including a title, description, and a list of speakers.

FMX

## Burning Belly PBL

- Case 1
- Case 2
- Questions

FMX

## Chief Complaint

- “My stomach hurts....”

FMX

## History of Present Illness

“Dawn”

- 48 yo F c/o chronic upper abd pain x 6 months
- Worse after she eats
- Getting full sooner
- Constant bloating



FMX

## AES Question

- What other history do you want?

FMX

## Past Medical History

- T2DM
- HTN
- Hypokalemia
- OA of bilateral knees

FMX

## Medications, Allergies

- Metformin
- Septra (recent UTI)
- HCTZ
- Pottasium Chloride
- OTC Motrin
- Allergy: NKDA

FMX

## AES Question

- Any potential culprits here?

FMX

## Medication Effect

- Metformin
- Antibiotics
- Bisphosphonates
- Steroids
- Iron
- Potassium Chloride
- NSAIDs

Lloyd RA, McCallan DA. Update on the Evaluation and Management of Functional Dyspepsia. Amer Fam Phys. 2011 March 1; 83(3): 547-52.

FMX

## Social History

- School teacher
- Married, 2 children
- No tobacco
- No etoh
- No illicit

FMX

## Review of Systems

- Constitutional: no fevers, chills, change in wt
- EENT: no blurred vision, rhinorrhea, tinnitus
- CV: no chest pain, palpitations
- Resp: no dyspnea, cough
- GI: +bloating, +early satiety, +pain
- GU: no dysuria
- MSK: +knee pain

FMX

## Physical Examination

Gen: A&Ox3 in NAD  
HEENT: PERRL, OP clear  
CV: RRR w/o m/g/r  
Resp: CTA-B  
Abd: soft, obese, ttp over epigastrium

FMX

- What is your differential diagnosis of likely causes for Dawn's epigastric pain?

FMX

## Differential Diagnosis

- Functional Dyspepsia ~ 70%
- PUD ~15%
- Reflux Esophagitis ~10%
- Gastric/Esophageal Cancer <2%
- Gastroparesis- Rare
- Pancreatitis- Rare
- Medication Effect

Lloyd RA, McClellan DA. Update on the Evaluation and Management of Functional Dyspepsia. Amer Fam Phys. 2011 March 1; 83(3): 547-52.

FMX

- What is the likely diagnosis?
- Is an EGD needed?
- What other diagnostics would you perform?

FMX

## ROME III Criteria

- One or More of the Following:
  - Postprandial fullness
  - Early satiation
  - Epigastric pain
  - Epigastric burning
- AND no evidence of structural disease
- Criteria met for the last 3 months and onset at least 6 months prior to diagnosis

ROME III Diagnostic Criteria for Functional Gastrointestinal Disorders. [http://romecriteria.org/assets/pdf/19\\_romeiii\\_apa\\_885-898.pdf](http://romecriteria.org/assets/pdf/19_romeiii_apa_885-898.pdf).

FMX

## Dyspepsia Diagnostics

- EGD indicated for Alarm Features
  - >55 years old
  - Bleeding, anemia, >10% wt loss, progressive dysphagia
  - History of cancer or PUD
  - Abdominal mass on exam

Lloyd RA, McClellan DA. Update on the Evaluation and Management of Functional Dyspepsia. Amer Fam Phys. 2011 March 1; 83(3): 547-52.

FMX

## H. Pylori Testing

Test	Sensitivity	Specificity
Serum	85%	79%
Breath	95%	98%
Stool	94%	92%

Talley NJ, Vakil N. Guidelines for the Management of Dyspepsia. Amer J of Gastro. 2005; 2224-35.

FMX

## Follow Up #1

- H. pylori negative
- No EGD indicated
- Trial of treatment

FMX

## AES Question

- What would you prescribe or try?


FMX

## Management

- Acid Suppression
- Prokinetics
- Eradication of H. Pylori
- Psychotropics
- Psychological interventions

Lloyd RA, McClellan DA. Update on the Evaluation and Management of Functional Dyspepsia. Amer Fam Phys. 2011 March 1; 83(5): 547-52.

FMX



FMX

## Burning Belly PBL

- Case 1
- Case 2
- Questions

FMX

## Chief Complaint

- “I have horrible heartburn...”

FMX

## History of Present Illness

”Jim”

- 32 yo M w/ chronic heartburn
- Worse at end of day
- Avoids spicy foods
- Present over 10 years
- Getting worse



FMX

## Past Medical History

- PMHx: HTN
- PSHx: tonsillectomy

FMX

## Medications, Allergies

- HCTZ
- OTC antacids
- NKDA

FMX

## Family History

- No history of GI malignancies

FMX

## Social History

- plumber
- Smokes 2 ppd
- Drinks 3-4 mixed drinks/day
- More on weekend

FMX

## Review of Systems

- Constitutional: no fevers, chills, no wt loss
- EENT: no blurred vision, rhinorrhea, tinnitus
- CV: no chest pain, palpitations
- Resp: no dyspnea, chronic cough
- GI: +heartburn, no odynophagia, no melena
- GU: no dysuria
- MSK: +knee pain

FMX

## Physical Examination

- Malodorous breath
- Poor dentition
- Wheezing

FMX

### AES Question

- What is in your differential diagnosis?

FMX

### Non-GERD causes

- Achlasia or Esophageal Dismotility
- EOE
- Reflux-like Dyspepsia
- Gastroparesis
- Cardiac

Subramanian CR, Triadafilopoulos. Refractory Gastroesophageal Reflux Disease. Gastroenterology Report 3. 2014 Sep 30; 41-53

FMX

### AES Question

- How would you treat this?

FMX

### Follow up #1

- Its been 8 weeks
- Initially helped
- Symptoms returning

FMX

### AES Question

- What do you want to do now?

FMX

### Reasons PPIs Fail

- Noncompliance
- Inadequate dosing
- Taking medication incorrectly
- Non-adherence to lifestyle modifications
- Increased volume reflux

Subramanian CR, Triadafilopoulos. Refractory Gastroesophageal Reflux Disease. Gastroenterology Report 3. 2014 Sep 30; 41-53

FMX

## Risk Factors for Refractory Disease

- Increased BMI
- Sliding hiatal hernia
- Esophageal hypersensitivity
- Ineffective Esophageal Peristalsis
- Ultrastructural and functional change in esophageal epithelium

FMX

## Treating Refractory Disease

- Double PPI
- Extended Release PPIs
- Alternate PPI
- Add night time H2RA as needed
- Prokinetics

Subramanian CR, Triadafilopoulos. Refractory Gastroesophageal Reflux Disease. Gastroenterology Report 3. 2014 Sep 30; 41-53

FMX

## Noncompliance

- Not Always the patient
  - Minimal time educating
  - Excessive medical jargo or unclear instructions
- Health Coaching
- Shared Decision Making
- Close the loop

FMX

## Follow up #2 & #3

- Despite trying alternate ppi and adding H2 blocker patient still having symptoms
- Worked with health coach in the clinic and adhering to lifestyle changes
- Now complaining of food getting “Stuck” occasionally


FMX

## AES Question

- Would you recommend EGD? Why?

FMX

## Erosive Esophagitis



FMX



## AES Question

- What other tests should you consider?

FMX

## Functional Evaluation

- Manometry
- Ambulatory pH/Impedance monitoring
- EndoFLIP
- Gastric Scintigraphy

Subramanian CR, Triadafilopoulos. Refractory Gastroesophageal Reflux Disease. Gastroenterology Report 3. 2014 Sep 30; 41-53

FMX


## High Resolution Manometry

- Evaluate for motor disorders/Peristalsis
- Closely spaced pressure sensors
- Chicago Classification for severity

Reproduced with permission from: Kahrlitz P. High Resolution Manometry. In: UpToDate, Basow DS (Ed), UpToDate, Waltham, MA. (Accessed on [May 30, 2015]). Copyright © 2015 UpToDate, Inc. For more information visit [www.uptodate.com](http://www.uptodate.com).

FMX

Conventional manometry and high resolution manometry with esophageal pressure topography



Manometry quantifies esophageal and LES pressure during swallowing to detect abnormalities of peristalsis and sphincter relaxation. Conventional manometry utilized 5 cm spaced pressure sensors that drop in resolution on the left and right sides of the esophageal lumen. High-resolution manometry (HRM) utilizes 1 cm spaced pressure sensors that drop in resolution on the left and right sides of the esophageal lumen. HRM provides a more detailed and accurate representation of esophageal pressure. The color-coded pressure topography map on the right panel with pressure profiles as a continuous map along the entire length of the esophagus. The color-coded map shows pressure changes over time and space, allowing for the identification of specific esophageal motility disorders.

UpToDate

FMX

## pH monitoring


- Catheter based (24 hrs)
- Wireless (48 hrs+)
- May evaluate on and off PPI

FMX

## Impedance Monitoring

- Detects Retrograde bolus movement
- Usually combined with pH probe
  - Increases diagnostic yield by 17%

Acid and non-acid reflux identified by combined MII pH monitoring



Reflux is identified by changes in impedance progressing distally to proximally as fluid advances from the stomach into the esophagus. Information from the pH electrode is used to identify acid vs. non-acid. pH drops from above to below 4) or non-acid (ie, pH remains above 4).

UpToDate

Reproduced with permission from: Tatum R. Esophageal multichannel intraluminal impedance testing. In: UpToDate, Basow DS (Ed), UpToDate, Waltham, MA. (Accessed on [May 30, 2015]). Copyright © 2015 UpToDate, Inc. For more information visit [www.uptodate.com](http://www.uptodate.com).

FMX

## EndoFLIP

- Cylindrical bag placed in distal esophagus
- Detects increased distension in EGJ
- Evaluation for large volume reflux
- Helpful for assessment of need for surgery

Subramanian CR, Triadafilopoulos. Refractory Gastroesophageal Reflux Disease. Gastroenterology Report 3. 2014 Sep 30; 41-53

FMX

## Follow up #4

- Abulatory ph and Impedence testing +
- Pt is concerned nothing will help

FMX

## AES Question

- How often does ppi therapy fail?
- Is he a candidate for surgery?

FMX

## Fundoplication


- Create per esophageal ring around GEJ
- LOTUS trial
  - Lower rates of heartburn/reflux at 5 yrs
- Complications
  - Dysphagia- Early vs Late
  - Gas Bloat Syndrome
  - Return of symptoms at 10 yrs-10%

Subramanian CR, Triadafilopoulos. Refractory Gastroesophageal Reflux Disease. Gastroenterology Report 3. 2014 Sep 30; 41-53.

FMX

## Partial Fundoplication

- Anterior
  - Less dysphagia and bloating
  - Similar heartburn scores/patient satisfaction
- Toupet (posterior)
  - Less dysphagia
  - Similar response rates
  - Surgery of choice BMI<40



Subramanian CR, Triadafilopoulos. Refractory Gastroesophageal Reflux Disease. Gastroenterology Report 3. 2014 Sep 30; 41-53. Reproduced with permission from: Schwelzberg SD. Surgical management of gastroesophageal reflux in adults. In: UpToDate, Boston, MA. UpToDate, Waltham, MA. Accessed on May 29, 2015. Copyright © 2015 UpToDate, Inc. For more information visit www.uptodate.com.

FMX

## Gastric Bypass

- Preferred anti reflux surgery for BMI>40
- BOLD
  - RGB-56%
  - Banding 46%
  - Sleeve 41%
- Lower post op complications

Subramanian CR, Triadafilopoulos. Refractory Gastroesophageal Reflux Disease. Gastroenterology Report 3. 2014 Sep 30; 41-53.

FMX

## Treatment Gap

- 40% Fail aggressive medical therapy
  - 5% undergo fundoplication
- Fear of complications or treatment failure
- Alternative treatment
  - LINX
  - EndoStim
  - Stretta
  - Medigus

Subramanian CR, Triadafilopoulos. Refractory Gastroesophageal Reflux Disease. Gastroenterology Report 3. 2014 Sep 30; 41-53.

FMX

## Practice Recommendations

- There is no significant difference in equivalent doses of PPIs for nonerosive GERD (SORT: A)
- Anti reflux surgery should be reserved if there are contraindications to PPIs or PPI therapy is insufficient to control symptoms (SORT: C)
- H. pylori should be tested and treated for dyspepsia, but not GERD alone (SORT: C)

FMX

## Burning Belly PBL

- Case 1
- Case 2
- Questions

FMX

## Practice Recommendations

- There is no significant difference in equivalent doses of PPIs for nonerosive GERD (SORT: A)
- Anti reflux surgery should be reserved if there are contraindications to PPIs or PPI therapy is insufficient to control symptoms (SORT: C)
- H. pylori should be tested and treated for dyspepsia, but not GERD alone (SORT: C)

FMX

## References

1. Subramanian CR, Triadafilopoulos. Refractory Gastroesophageal Reflux Disease. Gastroenterology Report 3. 2014 Sep 30; 41-53.
2. Loyd RA, McClellan DA. Update on the Evaluation and Management of Functional Dyspepsia. Amer Fam Phys. 2011 March 1. 83(5): 547-52.
3. Talley NJ, Vakili N. Guidelines for the Management of Dyspepsia. Amer J of Gastro. 2005: 2324-35.
4. Anderson WD, Strayer SM, et al. Common Questions about the Management of Gastroesophageal Reflux Disease. Amer Fam Phys. 2015 May 15. 91(10): 692-97.
5. Pietzak MM, et al. Stratifying risk for celiac disease in a large at risk United States population by using HLA alleles. Clin Gastroenterol Hepatol. 2009;7(9):966-971.
6. NIH Consensus Development Conference on Celiac Disease. NIH Consens State Sci Statements. 200; 21(1):1-23.
7. Bast A, O'Bryan T, et al. Celiac Disease and Reproductive Health. Pract Gastro. 2009 Oct: 10-18.

FMX

Jason Domagalski, MD,  
FAAFP

JDomagalski@mcw.edu

FMX

## Associated Session

- Gastroesophageal Reflux Disease: The Burning Belly, Review of GERD and Dyspepsia

**FMX**

Interested in More CME on this topic?  
**[aafp.org/fmx-internal](http://aafp.org/fmx-internal)**

**FMX**